# OnCo record nct06970782 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06970782/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06970782", "NCT06970782" ;
  schema:name "Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failur"@en ;
  schema:alternateName "KYLIN-3"@en ;
  schema:description "A phase 3 trial of vebreltinib and pemetrexed in lung cancer, run by Avistone Biotechnology Co., Ltd., not yet recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06970782/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06970782> ;
  onco:status "planned" ;
  onco:tag "ctgov-ingest", "lung-deep-dive" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/egfr-mutant-nsclc/>, <https://onco.cc/cancers/met-altered-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/vebreltinib/>, <https://onco.cc/drugs/pemetrexed/> ;
  onco:companies <https://onco.cc/companies/avistone-biotechnology/> .